---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016259"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:33:41.422396+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q2 net loss $14.9M, cash $131.9M; Phase 2b atacicept enrollment complete

## Summary
- Net loss of $14.9M ($0.55 per share) vs $3.4M ($0.33) in Q2 2021.
- Cash, equivalents, and securities $131.9M at June 30, 2022; plus $45M credit facility.
- Completed enrollment in Phase 2b ORIGIN trial of atacicept for IgA nephropathy; topline data expected early Q1 2023.
- Appointed Michael M. Morrissey, Ph.D., CEO of Exelixis, as Chairman of the board.
- Plan to initiate Phase 3 atacicept trial in lupus nephritis in H2 2022 and Phase 2b/3 MAU868 in BKV in 2023.

## SEC filing metadata
- accession: 0000950170-22-016259
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017022016259/0000950170-22-016259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017022016259/vera-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016259
- JSON: https://secwatch.observer/filing/0000950170-22-016259.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.